These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26114404)

  • 21. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
    Wang-Weigand S; Watissée M; Roth T
    Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
    Mini LJ; Wang-Weigand S; Zhang J
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
    Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
    J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin receptor agonists for treating delirium in elderly patients with acute stroke.
    Ohta T; Murao K; Miyake K; Takemoto K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1107-10. PubMed ID: 23017429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis.
    Fink T; Glas M; Wolf A; Kleber A; Reus E; Wolff M; Kiefer D; Wolf B; Rensing H; Volk T; Mathes AM
    Crit Care Med; 2014 Jan; 42(1):e22-31. PubMed ID: 24145838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramelteon (Rozerem) for insomnia.
    Med Lett Drugs Ther; 2005 Nov; 47(1221):89-91. PubMed ID: 16267494
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
    Fisher SP; Davidson K; Kulla A; Sugden D
    J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ramelteon: a review of its use in insomnia.
    Simpson D; Curran MP
    Drugs; 2008; 68(13):1901-19. PubMed ID: 18729542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.
    Imbesi M; Uz T; Dzitoyeva S; Manev H
    Neurosci Lett; 2008 Jul; 439(1):34-6. PubMed ID: 18501512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of delirium with ramelteon: initial experience in three patients.
    Kimura R; Mori K; Kumazaki H; Yanagida M; Taguchi S; Matsunaga H
    Gen Hosp Psychiatry; 2011; 33(4):407-9. PubMed ID: 21762839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T; Stubbs C; Walsh JK
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melatonin receptor activation suppresses adrenocorticotropin production via BMP-4 action by pituitary AtT20 cells.
    Tsukamoto N; Otsuka F; Ogura-Ochi K; Inagaki K; Nakamura E; Toma K; Terasaka T; Iwasaki Y; Makino H
    Mol Cell Endocrinol; 2013 Aug; 375(1-2):1-9. PubMed ID: 23701823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia.
    Richardson G; Wang-Weigand S
    Hum Psychopharmacol; 2009 Mar; 24(2):103-11. PubMed ID: 19090503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of suvorexant in the prevention of delirium during acute hospitalization: A systematic review.
    Adams AD; Pepin MJ; Brown JN
    J Crit Care; 2020 Oct; 59():1-5. PubMed ID: 32480359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successfully treated delirium in an extremely elderly patient by switching from risperidone to ramelteon.
    Tsuda A; Nishimura K; Naganawa E; Otsubo T; Ishigooka J
    Psychiatry Clin Neurosci; 2013 Feb; 67(2):130. PubMed ID: 23438172
    [No Abstract]   [Full Text] [Related]  

  • 36. Ramelteon as adjunctive therapy for delirium referred to a consultation-liaison psychiatry service: a retrospective analysis.
    Furuya M; Miyaoka T; Yasuda H; Wake R; Hashioka S; Miura S; Nagahama M; Araki T; Horiguchi J
    Int J Geriatr Psychiatry; 2015 Sep; 30(9):994-5. PubMed ID: 26220878
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of Ramelteon and Other Sleep-Promoting Drugs on Serum Low-Density Lipoprotein and Non-high-density Lipoprotein Cholesterol: A Retrospective Comparative Pilot Study.
    Torii H; Shimizu R; Tanizaki Y; Omiya Y; Yamamoto M; Kamiike S; Yasuda D; Hiraoka Y; Hashida T; Kume N
    Biol Pharm Bull; 2018; 41(12):1778-1790. PubMed ID: 30504680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ramelteon is Not Associated With Improved Outcomes Among Critically Ill Delirious Patients: A Single-Center Retrospective Cohort Study.
    Thom R; Bui M; Rosner B; Teslyar P; Levy-Carrick N; Wolfe D; Klompas M
    Psychosomatics; 2019; 60(3):289-297. PubMed ID: 30193784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
    Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The use of agomelatine for the preventive treatment of migraine].
    Turbina LG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(2):56-8. PubMed ID: 24662347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.